Clinical trials industry is constantly evolving, and also new clinical studies are being launched at an ever-growing pace. Clinical trial services have widely regarded as the principal method for obtaining a reliable evaluation of treatment effect on patients. Conducting clinical trials is a growing trend in the medical industry for testing the safety level and effectiveness of a newly developed medical device or drug. They provide the reliable basis for evaluating the efficacy and safety of new treatments in clinical trials industry. The historical perspective, present status, and future strategy for clinical trials provide a contextual framework.
Clinical research has always been at the forefront of medical advancements
The past five years have seen the AsiaPacific APAC region emerge as a global hub for clinical trials attracting pharmaceutical companies
Human factors engineering HFE is crucial in developing an effective device and is critical to meeting global regulatory expectations
Although slowly fading away from the collective memory the SARSCoV pandemic that started in early and the unprecedented health crisis on a global scale that followed reminded us about the necessity of pandemic preparedness
The definition concept and scope of controlled clinical trials in human beings is a relatively new one and has rapidly evolved during the last years
It is widely recognised that clinical trial success is dependent on patient recruitment
The pursuit for effective treatment modalities for cancer rides on sustained efforts with catalysed adoption of technological advancements that surpass traditional paradigms
Clinical trials are an integral part of drug development that decide the outcome of the newly developed or the newly formulated medicines
The complete human genome was published in March heralding a new era in pharmacogenomics advancing genome analysis and unlocking value additions in precision medicine
Recently a Drug Information Association American Statistical Associationsponsored Interdisciplinary Safety Evaluation working group published a recommended approach to the aggregate assessment of clinical trial safety data